Literature DB >> 16151025

Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.

Ryan E Moore1, Mohamad Navab, John S Millar, Francesca Zimetti, Susan Hama, George H Rothblat, Daniel J Rader.   

Abstract

To test the hypothesis that apolipoprotein A-I (apoA-I) functions specifically to inhibit atherosclerosis independent of the level of high-density lipoprotein cholesterol (HDL-C) by promoting both reverse cholesterol transport and HDL antiinflammatory function in vivo, we established a murine atherosclerosis model of apoA-I deficiency in which the level of HDL-C is well maintained. ApoA-I-/- mice were crossed with atherosclerosis susceptible low-density lipoprotein receptor-/-/apobec-/- (LA) mice to generate LA mice with apoA-I+/+, apoA-I+/-, and apoA-I-/- genotypes. There were no major differences in the amounts of non-HDL-C and HDL-C in the plasma between different apoA-I genotypes. A significant inverse relationship was observed, however, between apoA-I gene dose and atherosclerosis in both female and male mice. Compared with LA-apoA-I+/+ mice, serum from LA-apoA-I-/- mice had a significantly reduced capacity to function as an acceptor of ABCA1- and SR-BI-mediated cellular cholesterol efflux, and also had markedly reduced lecithin cholesterol acyltransferase activity. In addition, LA-apoA-I-/- mice had significantly reduced macrophage-derived cholesterol esterification and reverse cholesterol transport in vivo. There was significantly reduced plasma paraoxonase (PON-1) activity, impaired HDL vascular antiinflammatory function, and increased basal levels of monocyte chemotactic protein-1 in the plasma of LA-apoA-I-/- mice compared with LA-apoA-I+/+ mice. In LA-apoA-I-/- mice, there was also greater induction of some, but not all, inflammatory cytokines and chemokines in response to intraperitoneal injection of lipopolysaccharide than in LA-apoA-I+/+ mice. We conclude that apoA-I inhibits atherosclerosis by promoting both macrophage reverse cholesterol transport and HDL antiinflammatory function, and that these anti-atherogenic functions of apoA-I are largely independent of the plasma level of HDL-C in this mouse model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16151025     DOI: 10.1161/01.RES.0000185320.82962.F7

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  61 in total

1.  Ethanolic extract of propolis promotes reverse cholesterol transport and the expression of ATP-binding cassette transporter A1 and G1 in mice.

Authors:  Yang Yu; Yanhong Si; Guohua Song; Tian Luo; Jiafu Wang; Shucun Qin
Journal:  Lipids       Date:  2011-06-03       Impact factor: 1.880

2.  Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice.

Authors:  Mary G Sorci-Thomas; Manal Zabalawi; Manish S Bharadwaj; Ashley J Wilhelm; John S Owen; Bela F Asztalos; Shaila Bhat; Michael J Thomas
Journal:  Biochim Biophys Acta       Date:  2011-09-14

Review 3.  The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Authors:  Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
Journal:  J Lipid Res       Date:  2010-04-06       Impact factor: 5.922

4.  NADPH oxidase inhibition ameliorates Trypanosoma cruzi-induced myocarditis during Chagas disease.

Authors:  Monisha Dhiman; Nisha Jain Garg
Journal:  J Pathol       Date:  2011-09-26       Impact factor: 7.996

5.  THOC5: a novel gene involved in HDL-cholesterol metabolism.

Authors:  Maria Keller; Dorit Schleinitz; Julia Förster; Anke Tönjes; Yvonne Böttcher; Antje Fischer-Rosinsky; Jana Breitfeld; Kerstin Weidle; Nigel W Rayner; Ralph Burkhardt; Beate Enigk; Ines Müller; Jan Halbritter; Moritz Koriath; Andreas Pfeiffer; Knut Krohn; Leif Groop; Joachim Spranger; Michael Stumvoll; Peter Kovacs
Journal:  J Lipid Res       Date:  2013-09-10       Impact factor: 5.922

Review 6.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

Review 7.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

Review 8.  HDL, lipid peroxidation, and atherosclerosis.

Authors:  Baohai Shao; Jay W Heinecke
Journal:  J Lipid Res       Date:  2009-01-12       Impact factor: 5.922

9.  Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties.

Authors:  A Hoang; A J Murphy; M T Coughlan; M C Thomas; J M Forbes; R O'Brien; M E Cooper; J P F Chin-Dusting; D Sviridov
Journal:  Diabetologia       Date:  2007-06-20       Impact factor: 10.122

10.  Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice.

Authors:  Junichiro Tohyama; Jeffrey T Billheimer; Ilia V Fuki; George H Rothblat; Daniel J Rader; John S Millar
Journal:  Atherosclerosis       Date:  2008-09-27       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.